Free Trial
OTCMKTS:PPCB

Propanc Biopharma (PPCB) Stock Price, News & Analysis

Propanc Biopharma logo
$1.99 -1.16 (-36.83%)
As of 05/22/2025 11:14 AM Eastern

About Propanc Biopharma Stock (OTCMKTS:PPCB)

Key Stats

Today's Range
$1.99
$2.28
50-Day Range
$1.99
$11.00
52-Week Range
$1.25
$222.00
Volume
2,844 shs
Average Volume
1,327 shs
Market Capitalization
$37,810.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Receive PPCB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter.

PPCB Stock News Headlines

Propanc Biopharma Inc (PPCB)
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
VTXB Vortex Brands Co.
Propanc Biopharma, Inc. (PPCB)
See More Headlines

PPCB Stock Analysis - Frequently Asked Questions

Propanc Biopharma's stock was trading at $0.0002 at the beginning of 2025. Since then, PPCB stock has increased by 994,900.0% and is now trading at $1.99.
View the best growth stocks for 2025 here
.

Propanc Biopharma, Inc. (OTCMKTS:PPCB) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($12.50) earnings per share (EPS) for the quarter.

Shares of Propanc Biopharma reverse split before market open on Tuesday, May 23rd 2023. The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Propanc Biopharma investors own include T2 Biosystems (TTOO), AppYea (APYP), Avis Budget Group (CAR), PayPal (PYPL), Synthetic Biologics (SYN), Corbus Pharmaceuticals (CRBP) and Delcath Systems (DCTH).

Company Calendar

Last Earnings
5/15/2025
Today
5/23/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:PPCB
Employees
1
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-1,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.01) per share
Price / Book
-199.00

Miscellaneous

Free Float
869,584,000
Market Cap
$37,810.00
Optionable
Not Optionable
Beta
2.30
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (OTCMKTS:PPCB) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners